GoingToMeet

CNS is one of the largest and fastest growing therapeutic areas of the pharmaceutical market. The ageing of the baby-boom generation combined with new and emerging treatments for neurodegenerative disorders, including multiple sclerosis, Alzheimer’s disease and Parkinson’s disease, will lead to further expansion of the neurodegenerative therapies market.

CNS Clinical Trials conference you will examine the strategies offering the greatest potential for success in CNS drug development, and understand the specifi challenges currently faced by developers in this market. In order to enhance productivity in this fi eld, there has been an increased awareness of the need to align clinical and preclinical research to facilitate rapid development of new CNS drug therapies. Medical imaging is increasingly being used as a surrogate endpoint or biomarker of drug effi cacy in all phases of CNS trials, enabling CNS developers to make more timely decisions.